The study found that patients with IBS-C had significantly decreased serum GLP-1, which negatively correlated with abdominal pain scores. Biopsies revealed a significant down-regulation of the GLP-1 receptor in colonic mucosa. The study evaluated the efficacy and safety of ROSE-010 in alleviating IBS symptoms. The gene discussed is GLP1R; the disease is irritable bowel syndrome.